Source:http://linkedlifedata.com/resource/pubmed/id/11865638
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2002-2-27
|
pubmed:abstractText |
TS-1, a DPD inhibitory fluoropyrimidine, is a novel oral formation of 5-fluorouracil (5-FU). In patients with advanced gastric cancer, the response rate was reportedly over 40%. We report three cases of advanced gastric cancer treated using TS-1 in combination with a low-dose of cisplatinum (CDDP) that well responded. Case 1: A 62-year-old women underwent total gastrectomy. Ten weeks later, she suffered intestinal obstruction due to peritoneal recurrence of gastric cancer. Eighty mg of TS-1 in combination with bi-weekly administration of CDDP (10 mg) improved her intestinal obstruction. Case 2: A 50-year-old man suffered peritoneal recurrence of gastric cancer. Computed tomography (CT) showed intestinal obstruction, ascites, and hydronephrosis. After 100 mg of TS-1 in combination with bi-weekly administration of CDDP (20 mg) for 1 year, CT showed almost complete improvement of peritonitis carcinomatosa. Case 3: A 58-year-old man, who suffered advanced gastric cancer with peritonitis carcinomatosa, was administrated 100 mg of TS-1 in combination with bi-weekly administration of CDDP (20 mg). After 2 months of administration, remarkable improvement was observed in the upper gastrointestinal series. Adverse reactions, which were grade 1 for stomatitis, were observed only in case 1. All three patients are alive (case 1 and 2 have survived more than one year) and therapy is continuing. In conclusion, combined chemotherapy of TS-1 and low-dose CDDP was effective and well tolerable for advanced gastric cancer patients. It was suggested that effective biochemical modulation might be achieved by these two drugs.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Oxonic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/S 1 (combination),
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
301-4
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11865638-Adenocarcinoma,
pubmed-meshheading:11865638-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11865638-Cisplatin,
pubmed-meshheading:11865638-Drug Administration Schedule,
pubmed-meshheading:11865638-Drug Combinations,
pubmed-meshheading:11865638-Female,
pubmed-meshheading:11865638-Fluorouracil,
pubmed-meshheading:11865638-Humans,
pubmed-meshheading:11865638-Male,
pubmed-meshheading:11865638-Middle Aged,
pubmed-meshheading:11865638-Oxonic Acid,
pubmed-meshheading:11865638-Pyridines,
pubmed-meshheading:11865638-Stomach Neoplasms,
pubmed-meshheading:11865638-Tegafur
|
pubmed:year |
2002
|
pubmed:articleTitle |
[Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum].
|
pubmed:affiliation |
Dept. of Surgery, National Himeji Hospital.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|